Company:	**"SOPHARMA" AD**
Board of Directors:	**Ognian Donev, PhD** **Vessela Stoeva** **Alexander Tchaoushev** **Bissera Lazarova** **Boris Borisov**
Executive Director:	**Ognian Donev, PhD**
Procurator:	**Simeon Donev**
Finance Director:	**Dimitar Bogomilov**
Chief Accountant:	**Diana Evlogieva**
Head of Legal Department	**Alexander Yotov**
Registered Office:	**Sofia** **16, Iliensko Shousse Str.**
Lawyers:	**Ventsislav Stoev** **Stefan Vachev**
Servicing Banks:	**UBB AD** **DSK Bank EAD** **Eurobank and FG Bulgaria AD** **ING Bank N.V.** **UniCredit AD** **Citibank N.A.**
Auditors:	**Baker Tilly Clitou and Partners OOD**
Executive Director:	**/signature/** **Ognian Donev, PhD**
Finance Director:	**/signature/** **Dimitar Bogomilov**
Prepared by:	**/signature/** **Jordanka Petkova**

"SOPHARMA" AD

INDIVIDUAL STATEMENT OF COMPREHENSIVE INCOME
for the period ended on 30 September 2026

	Notes	2026 EUR'000	2025 EUR'000
Revenue	3	132,211	99,969 *
Other operating income/(losses), net	4	8,946	5,002 *
Changes in inventories of production and work in progress		(326)	5,799
Raw materials and consumables used	5	(27,870)	(30,321)
Hired services expense	6	(25,312)	(19,782)
Employee benefits expense	7	(33,520)	(30,659)
Depreciation and amortisation expense	15,16	(11,542)	(8,116)
Carrying amount of distributed pharmaceutical products	8	(10,810)	(2,641) *
Other operating expenses	9	(2,611)	(2,295)
Profit from operations		**29,166**	**16,956**
Net profit/(loss) on sale of investments in subsidiaries and associates	18,19	2,902	1,621
Impairment of non-current assets outside the scope of IFRS 9	10	-	(147)
Finance income	11	2,607	3,706
Finance costs	12	(3,334)	(3,286)
Finance income / (costs), net		**(727)**	**420**
Profit before income tax		**31,341**	**18,850**
Income tax expense	13	(2,931)	(1,706)
Net profit for the year		**28,410**	**17,144**
Other comprehensive income:			
Items that will not be reclassified to profit or loss:			
Net change in fair value of other long-term equity investments	20	3,212	(2,039)
Subsequent revaluations of property, plant and equipment (PPE)	15	170	-
Income tax relating to items of other comprehensive income that will not be reclassified to profit or loss	13	(17)	
Other comprehensive income for the year, net of tax	14	**3,365**	**(2,039)**
TOTAL COMPREHENSIVE INCOME FOR THE YEAR		**31,775**	**15,105**
Basic earnings per share	29	**0.05**	**0.08**
Net earnings per diluted share	29	**0.05**	**-**

The accompanying notes on pages 5 to 146 from an integral part of the individual financial statements.
**** reclassification***

"SOPHARMA" AD

INDIVIDUAL STATEMENT OF FINANCIAL POSITION
as at 30 September 2026

	Notes	30 September 2026 EUR '000	31 December 2025 EUR '000
ASSETS			
Non-current assets			
Property, plant and equipment	15	109,331	108,726
Intangible assets	16	89,226	90,108
Investment property	17	25,791	25,777
Investments in subsidiaries	18	74,029	73,916
Investments in associates and joint ventures	19	40,269	54,981
Other long-term equity investments	20	8,105	4,957
Long-term receivables from related parties	21	6,814	6,691
Other long-term receivables	22	1,762	1,730
		355,327	**366,886**
Current assets			
Inventories	23	62,220	62,287
Receivables from related parties	24	56,989	59,466
Trade receivables	25	8,814	9,324
Loans granted to third parties	26 (a)	5,773	5,647
Other receivables and prepayments	26 (b)	7,205	4,843
Non-current assets held for trading	27	-	3,882
Cash and cash equivalents	28	7,993	13,328
		148,994	**158,777**
TOTAL ASSETS		**504,321**	**525,663**
EQUITY AND LIABILITIES			
EQUITY			
Basic share capital		274,970	275,667
Treasury shares		-	(9,311)
Reserves		40,618	47,380
Other capital components (reserve from issued warrants)		3,731	-
Retained earnings		45,542	17,946
	29	**364,861**	**331,682**
LIABILITIES			
Non-current liabilities			
Long-term bank loans	30	52,357	45,351
Deferred tax liabilities	31	1,744	1,117
Government grants	32	1,565	1,729
Liabilities under leasing contracts to related parties	33	5,904	6,682
Liabilities under leasing contracts to third parties	34	1,024	1,092
Long-term liabilities to staff	35	3,828	3,669
Tax liabilitirs	39	-	537
		66,422	**60,177**
Current liabilities			
Short-term bank loans	36	40,292	57,321
Short-term part of long-term bank loans	30	10,564	22,256
Trade payables	37	9,400	16,374
Payables to related parties	38	2,571	18,324
Tax payables	39	1,345	2,338
Payables to personnel and for social security	40	5,333	5,673
Non-current liabilities held for sale	41	-	849
Other current liabilities	42	3,533	10,669
		73,038	**133,804**
TOTAL LIABILITIES		**139,460**	**193,981**
TOTAL EQUITY AND LIABILITIES		**504,321**	**525,663**

The accompanying notes on pages 5 to 146 from an integral part of the individual fiancial statements.

"SOPHARMA" AD

INDIVIDUAL STATEMENT OF CASH FLOWS
for the period ended on 30 September 2026

	Notes	2026 EUR'000	2025 EUR'000
Cash flows from operating activities			
Cash receipts from customers		145,805	107,114
Cash paid to suppliers		(74,119)	(56,818)
Cash paid to employees and for social security		(33,133)	(29,947)
Taxes paid (except income taxes)		(3,610)	(3,122)
Taxes refunded (except income taxes)		3,754	1,957
Income taxes paid/(refunded)		(3,286)	305
Paid interest and bank charges on working capital loans		(1,305)	(1,280)
Exchange rate differences, net		10	(121)
Other proceeds/(payments), net		(344)	1,428
Net cash flows from operating activities		**33,772**	**19,516**
Cash flows from investing activities			
Proceeds from the sale of a separate business unit		2,255	-
Purchases of property, plant and equipment		(8,361)	(8,753)
Proceeds from sales of property, plant and equipment		4	262
Purchases of intangible assets		(5,071)	(46,423)
Purchases of investment property		(21)	(331)
Purchases of shares in associates		(39)	(339)
Proceeds from the sale of shares in associates		17,575	1,347
Proceeds from sale of other long-term capital investments		64	660
Purchases of shares and equity interests in subsidiaries		(207)	(24,741)
Proceeds from the sale of shares in subsidiaries		262	880
Dividends received from investments in associates		849	1,896
Dividends received from a civil partnership established for joint activities		66	-
Dividends received from other long-term capital investments		20	20
Loans granted to related parties		(330)	(153)
Repayment of loans granted to related parties		-	1,534
Loans granted to third parties		-	(54)
Repayment of loans granted to third parties		20	308
Interest received on loans granted		1	163
Proceeds from the sale of financial assets held for trading		-	1
Proceeds from guarantee fees		21	65
Net cash flows from / (used in) investment activities		**7,108**	**(73,658)**
Cash flows from financing activities			
Proceeds from issued capital		-	1,307
Proceeds from long-term bank loans		-	9,679
Repayment of long-term bank loans		(7,949)	(3,521)
Repayment / (Proceeds) of short-term bank loans (overdraft), net		(13,690)	27,482
Interest and fees paid on loans for investment purposes		(1,537)	(1,808)
Treasury shares		-	(1)
Proceeds from sale of treasury shares		25,604	23,455
Dividends paid and unexercised warrants		(51,126)	(6,899)
Lease payments to related parties		(908)	(889)
Lease payments to third parties		(437)	(377)
Proceeds / (payments), net, related to other capital components (warrants)		3,828	(7)
Net cash flows (used in) / from financial activities		**(46,215)**	**48,421**
Net increase/(decrease) in cash and cash equivalents		**(5,335)**	**(5,721)**
Cash and cash equivalents at 1 January		13,328	6,522
Cash and cash equivalents at 30 September	28	**7,993**	**801**

The accompanying notes on pages 5 to 146 from an integral part of the individual fiancial statements.

"SOPHARMA" AD

INDIVIDUAL STATEMENT OF CHANGES IN EQUITY

for the period ended on 30 September 2026

	Notes	Main equity capital	Treasury sahres	Statutory reserves	Revaluation reserve - property, plant and equipment	Reserve from financial assets at fair value through other comprehensive income	Additional reserves	Other equity components (reserve on warrants issue)	Retained earnings	Total owners' equity
		EUR'000	EUR'000	EUR'000	EUR'000	EUR'000	EUR'000	EUR'000	EUR'000	EUR'000
Balance as at 1 January 2025 (initially reported)		**91,572**	**(27,384)**	**111,885**	**10,255**	**(48)**	**115,823**	**133**	**8,913**	**311,149**
Changes in equity for 2025										
Capital issued, including:	29	184,095	-	(66,897)	-	-	(115,823)	(117)	-	1,258
- from exercised warrant rights		316	-	1,058	-	-	-	(117)	-	1,258
- from reserves		183,778	-	(67,955)	-	-	*(115,823)*	-	-	-
Effects of sold and repurchased own shares, including:		-	18,073	-	-	-	-	-	14,136	32,209
- treasury shares sold		-	18,074	-	-	-	-		14,136	32,210
- treasury shares acquired		-	(1)	-	-	-	-	-	-	*(1)*
Other capital components, incl.		-	-	9	-	-	-	(16)	-	(7)
- deregisterred warrants				*9*				*(9)*		-
- transactional exepnses		-	-	-	-	-	-	*(7)*		*(7)*
Distribution of profit for:		-	-	(10,823)	-	-	3,312	-	(23,122)	(30,633)
- dividends from the profit from 2024		-	-		-	-	-	-	*(6,987)*	(6,987)
- six-month dividend from the 2025 profit		-	-	*(10,823)*	-	-	-	-	*(12,823)*	(23,646)
- reserves		-	-	-	-	-	*3,312*	-	*(3,312)*	-
Total comprehensive income for the year, including:		**-**	**-**	**-**	**-**	**(508)**	**-**	**-**	**18,214**	**17,706**
- net profit for the year		-	-	-	-	-	-	-	*18,576*	*18,576*
- other components of comprehensive income, net of taxes		-	-	-		*(508)*	-	-	*(362)*	*(870)*
Transfer to retained earnings		-	-	-	(129)	324	-	-	(195)	-
Balance as at 31 December 2025	29	**275,667**	**(9,311)**	**34,174**	**10,126**	**(232)**	**3,312**	**-**	**17,946**	**331,682**
Changes in equity for 2026										
Effects of recalculation of the share capital		(697)	-	-	-	-	-	-	697	-
Effects of sold and repurchased own shares, including:		-	9,311	-	-	-	-	-	16,293	25,604
- treasury shares sold		-	*9,311*	-	-	-	-		*16,293*	*25,604*
Effects of sold rights from issued warrants		-	-	-	-	-	-	-	4	4
Other capital components, incl.		-	-	-	-	-	-	3,731	-	3,731
- issue value		-	-	-	-	-	-	*3,774*	-	*3,774*
- transactional expenses		-	-	-	-	-	-	*(43)*	-	*(43)*
Distribution of profit for:		-	-	(6,677)	-	-	(3,312)	-	(17,946)	(27,935)
- dividends from profit for 2025		-	-		-	-	-	-	*(5,752)*	(5,752)
- reserves		-	-	-	-	-	*12,194*		*(12,194)*	-
- dividends from reserves		-	-	-	-	-	*(22,183)*	-	-	(22,183)
- transfer of reserves		-	-	*(6,677)*	-	-	*6,677*	-		-
Total comprehensive income for the year, including:		**-**	**-**	**-**	**153**	**3,212**	**-**	**-**	**28,410**	**31,775**
- net profit for the year		-	-	-	-	-	-	-	*28,410*	*28,410*
- other components of comprehensive income, net of taxes		-	-	-	*153*	*3,212*	-	-	-	*3,365*
Transfer to retained earnings		-	-	-	(139)	1	-	-	138	-
Balance as at 30 September 2026	29	**274,970**	**-**	**27,497**	**10,140**	**2,981**	**-**	**3,731**	**45,542**	**364,861**

The accompanying notes on pages 5 to 146 from an integral part of the individual fiancial statements.